Pfizer Inc. (NYSE:PFE) registered a -0.09% decrease, still its new closing price is 16.50% up from the company’s 1 year high of 36.72.It posted -4.22% losses in previous 5 sessions and is now the subject of 11 analysts who together assign a hold rating on stock. 0 of Wall Street analysts have an underperform rating; the 0 sells versus 4 buy or better ratings. The 22 stock analysts following this company have an average price target at $37.65, with individual PT in the $30.00-$53.00 range. The shares moved at $32.03, implying that brokerage firms see shares gaining about 8.31% in twelve months time.
Pfizer Inc. (PFE) SEC Form 4 News
The stock is getting much attention these days as insiders are offloading shares while they posted a -1.39% fall year to date. A Executive Vice President at Pfizer Inc. (PFE) offloaded shares in a transaction closed on Wednesday November 09, 2016. MADDALUNA ANTHONY J sold 10,000 shares in the company at $33 each and collected $330,000 in proceeds. MADDALUNA ANTHONY J now owns 166,789 shares in the company after this transaction. A Group President in the company, BOURLA ALBERT, disclosed a transaction on Friday November 04, 2016 that ended up generating $552,001 from the sale of 18,390 shares at $30.05 per share.
Pfizer Inc. (NYSE:PFE) Upcoming Results on Tap
Pfizer Inc. will next provide financial results for the March 2017 quarter. Stock analysts expect it to report per-share earnings of $0.67 in that period. Sales during the quarter are predicted to arrive at $13.5 billion.
Earnings surprise history: Last quarter, the company posted approximately $13.05 billion in revenue and EPS of $0.61. The mean forecast was for $13.04 billion and $0.62 a share, respectively. One quarter earlier, revenue for the stock was at $13.15 billion, with earnings at $0.64/share.
Pfizer Inc. (PFE) Brokerage Update
Pfizer Inc. (PFE) is in Argus’s research list so their analyst rating change is noteworthy. These shares were downgraded to Hold from Buy by Argus, according to news reported on Wednesday November 02, 2016.Another important research note was issued by Jefferies on Thursday October 13, 2016.The firm downgraded PFE to Hold from Buy. Over the last six months and over the last three months, the shares of Pfizer Inc. (PFE), have changed -10.98% and -0.46%, respectively.
On January 6, 2017, ICU Medical, Inc. (ICUI) announced that ICU Medical and Pfizer Inc. (NYSE:PFE) have modified the terms of the definitive agreement entered into on October 6, 2016, under which ICU Medical will acquire the Hospira Infusion Systems (HIS) business from Pfizer. These modifications are a result of recent changes in performance of HIS that affect previously announced expectations for the transaction.
Under the terms of the modified agreement, the aggregate purchase price will be adjusted to be no more than $900 million (versus $1 billion as originally agreed). Upon closing, Pfizer will receive $400 million in equity (based upon the 30-day volume weighted average price through October 5, 2016, the day prior to announcement of the proposed transaction) in the form of 3.2 million newly issued ICU Medical shares (as originally agreed) and $275 million in cash (versus $600 million as originally agreed), which will be financed with existing cash balances and a $75 million seller note. Pfizer may be entitled up to an additional $225 million based on achievement of performance targets for the combined company through December 31, 2019, which would be payable after that date if performance is within the agreed target range. The transaction will require no external financing other than the seller note. ICU Medical expects to have approximately $150 million net cash and $225 million total cash at the close of the transaction. ICU Medical has received U.S. and other antitrust clearances needed for the completion of the transaction and expects the transaction to close in February 2017.
